Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. 1996

J D Klausner, and V H Freedman, and G Kaplan
Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York 10021-6399, USA.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

J D Klausner, and V H Freedman, and G Kaplan
January 1998, Archiv der Pharmazie,
J D Klausner, and V H Freedman, and G Kaplan
January 2000, Arthritis research,
J D Klausner, and V H Freedman, and G Kaplan
December 2007, Australian family physician,
J D Klausner, and V H Freedman, and G Kaplan
January 2004, Acta neurobiologiae experimentalis,
J D Klausner, and V H Freedman, and G Kaplan
January 2008, Current medicinal chemistry,
J D Klausner, and V H Freedman, and G Kaplan
January 2002, Journal of cellular and molecular medicine,
J D Klausner, and V H Freedman, and G Kaplan
February 2006, Clinical science (London, England : 1979),
J D Klausner, and V H Freedman, and G Kaplan
January 1996, Chirality,
J D Klausner, and V H Freedman, and G Kaplan
January 1999, International journal of dermatology,
J D Klausner, and V H Freedman, and G Kaplan
August 2000, Microscopy research and technique,
Copied contents to your clipboard!